论文部分内容阅读
目前,降血脂药物在临床上应用很多,但效果并非十分理想,并且副作用较多。我科于1989年1月至1991年12月期间,系统地观察了降血脂药物非诺贝特对48例高脂血症病人之血清脂质(Tch,TG及HDL-ch)水平的影响,现总结如下: 1 观察对象与方法 所观察的48例高脂血症病人,男32例,女16例,年龄40～78岁,平均年龄64.72岁。其中冠心病高脂血症38例,糖尿病高脂血症9例,原发性高脂血症1例,均口服嘉兴制药厂生产的非诺贝特每次100mg,一天3次,疗程一月。
At present, lipid-lowering drugs in clinical applications, but the effect is not very good, and more side effects. In our department from January 1989 to December 1991, we systematically observed the effects of fenofibrate, a lipid-lowering drug, on serum lipids (Tch, TG and HDL-ch) in 48 patients with hyperlipidemia. Are summarized as follows: 1 observed objects and methods observed in 48 cases of hyperlipidemia patients, 32 males and 16 females, aged 40 to 78 years, mean age 64.72 years. One 38 cases of coronary heart disease hyperlipidemia, diabetes, hyperlipidemia in 9 cases, 1 case of primary hyperlipidemia, are oral administration of fenofibrate Jiaxing pharmaceutical factory every 100mg, 3 times a day, treatment January .